Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy

 

 Buy Article Permissions and Reprints

Surgical resection is regarded as the first-line curative treatment for early-stage hepatocellular carcinoma (HCC). However, the lack of sufficient future liver remnant (FLR) in many patients would preclude them from surgical candidacy. Yttrium-90 radiation lobectomy (RL) has been established over the past decade as an effective method to achieve tumor control as well as achieving FLR hypertrophy, while embedding a test-of-time. Most recently, Yttrium-90 radiation segmentectomy (RS) has been proven potentially curative in early-stage HCC. In this article, we highlight a modified radiation lobectomy (mRL) which is a combined approach of RL and RS that aims at concurrent achievement of complete tumor necrosis and FLR hypertrophy.

Radioembolization has historically been employed in the salvage setting for the treatment of unresectable hepatic malignancies. In this approach, lobar hepatic therapies have been found to offer palliative intent.[1] Observations of an atrophy–hypertrophy complex following this lobar therapy have led to a concept termed “radiation lobectomy”; the treated hepatic lobe will atrophy following radioembolization and the contralateral, untreated, hepatic lobe provides compensatory hypertrophy. This finding has allowed for the application of RL as an alternative to portal vein embolization (PVE), particularly in HCC, which can provide concurrent cancer therapy while promoting hypertrophy of the contralateral FLR for planned surgical resection in patients initially presenting with an FLR insufficient to sustain hepatic function postoperatively.[2] [3] [4]

Described in 2010, RS[5] is a technique increasingly used to treat liver tumors in a segmental rather than lobar fashion. RS has demonstrated safety and efficacy, with good imaging response rates, long time to tumor progression posttreatment, and high rates of explant complete pathologic necrosis.[6] [7] More recently, segmental radioembolization with glass microspheres has been described with curative intent in patients with unresectable HCC.[8]

In this article, we highlight a modified approach to RL combining both lobar and segmental Y90 delivery to promote curative tumor therapy while inducing contralateral hypertrophy to facilitate surgical resection. These approaches have been most commonly performed and reported in the literature employing glass microsphere radioembolization (TheraSphere, Biocompatibles UK Ltd) for patients with unresectable HCC.[9]

• References

• 1 Salem R, Lewandowski RJ, Mulcahy MF. , et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
  CrossrefPubMedGoogle Scholar
• 2 Gaba RC, Lewandowski RJ, Kulik LM. , et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol 2009; 16 (06) 1587-1596
  CrossrefPubMedGoogle Scholar
• 3 Lewandowski RJ, Donahue L, Chokechanachaisakul A. , et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol 2016; 114 (01) 99-105
  CrossrefPubMedGoogle Scholar
• 4 Vouche M, Lewandowski RJ, Atassi R. , et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol 2013; 59 (05) 1029-1036
  CrossrefPubMedGoogle Scholar
• 5 Riaz A, Gates VL, Atassi B. , et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79 (01) 163-171
  CrossrefPubMedGoogle Scholar
• 6 Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
  CrossrefPubMedGoogle Scholar
• 7 Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol 2014; 25 (07) 1067-1073
  CrossrefPubMedGoogle Scholar
• 8 Lewandowski RJ, Gabr A, Abouchaleh N. , et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
  CrossrefPubMedGoogle Scholar
• 9 TheraSphere^® Yttrium-90 Glass Microspheres [package insert]. Farnham, Surrey, UK: Biocompatibles UK Ltd., Rev 14. Available at: https://www.btg-im.com/BTG/media/TheraSphere-Documents/PDF/TheraSphere-Package-Insert_USA_Rev-14.pdf . Accessed September 5, 2019
  PubMed
• 10 Farges O, Belghiti J, Kianmanesh R. , et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237 (02) 208-217
  PubMedGoogle Scholar
• 11 de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM. Induction of tumor growth after preoperative portal vein embolization: is it a real problem?. Ann Surg Oncol 2009; 16 (02) 423-430
  CrossrefPubMedGoogle Scholar
• 12 Hayashi S, Baba Y, Ueno K. , et al. Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol 2007; 48 (07) 721-727
  CrossrefPubMedGoogle Scholar